Wednesday 8 June 2016, Amsterdam
The Report, now available on ASDReports, “In Vitro Toxicology Testing Market by Product, Type (ADME), Toxicity Endpoints & Tests (Carcinogenicity, Dermal Toxicity, Genotoxicity), Technology (Genomics, Transcriptomics), Method (Cellular Assays), Industry (Pharmaceutical) - Global Forecast to 2021”, report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the global in vitro toxicology testing market along with the estimates and forecasts of the revenue and market share analysis.
The global in vitro toxicology testing market is expected to reach USD 27.36 Billion by 2021 from USD 14.15 Billion in 2016, at a CAGR of 14.1% from 2016 to 2021. Opposition to animal testing, new & promising technologies, increasing R&D to detect toxicity at early stages and insufficient databases to facilitate the use of in vitro test methods are the primary growth drivers for this market during the forecast period (2016–2021). However, lack of in vitro models to detect autoimmunity and immunostimulation and predictive ability of in vitro testing over in vivo testing may hinder the growth of this market.
The global in vitro toxicology testing market is segmented on the basis of products, type, toxicity endpoints & tests, technology, method, and industry. On the basis of product, the market is segmented into assays, reagent & labware and services. Of these, the assays product segment accounted for the largest share of the global in vitro toxicology testing market in 2016, large share of this segment can primarily be attributed to the to the increasing use of assays for testing various toxicity endpoints and the higher frequency of purchase of these assays as compared to reagents & labware. On the basis of industry, the market is segmented into cosmetics & household products, pharmaceutical, diagnostics, chemical, & food. Of these, the cosmetics & household products industry segment accounted for the largest share of the global in vitro toxicology testing market in 2016, large share of this segment is due to the compulsory ban of animal testing across the cosmetics industry with a ban on marketing finished products and cosmetic ingredients.
By method, the market is divided into in silico method, biochemical assays, cellular assays, and ex vivo models. Of these, in silico methods accounted for the largest growing segment in the global in vitro toxicology testing market by 2021. On the basis of toxicity endpoints & tests, the in vitro toxicology testing market is categorized into systemic toxicity, dermal toxicity, carcinogenicity, ocular toxicity, skin sensitization & irritation, genotoxicity, neurotoxicity, and organ toxicity.
The geographic segments included in this report are Europe, North America, Asia, and Rest of the World (RoW). Geographic analysis reveals that Europe accounted for the largest share of the global in vitro toxicology testing market in 2016. Growth in this market can be attributed to the opposition of animal testing, and increasing R&D to detect toxicity at early stages.
The major players in this market include Agilent Technologies, Inc. (U.S.), Covance, Inc. (A subsidiary of LabCorp) (U.S.), Bio-Rad Laboratories, Inc. (U.S.), General Electric Company (U.S.), Eurofins Scientific SE (Luxembourg), BioReliance, Inc. (A subsidiary of Merck & Co, Inc.) (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.).
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News